Cellular Biological Basis and Novel Breakthroughs in the Pathogenesis of Myopia — A Narrative Review Authors: Wen Liu, Qi Hu, Peijuan Wu, Dan Wang, Zhixin Peng, Zhimin Liu, Xiangdong Chen Published: 2026 ABSTRACT AbstractMyopia has evolved into a severe global public health concern, exhibiting an epidemiological trend of earlier onset and higher refractive errors particularly among adolescents. Complications induced by high myopia, such as retinal detachment and macular degeneration, pose grave threats to visual health. This paper is a narrative review. It summarizes advances in the cell biology of myopia, elucidates the mechanisms underlying myopia mediated by multiple intraocular cell types, interprets several interactive regulatory pathways, and reviews biomarkers, targeted interventions and detection technologies. Different from previous reviews, this paper links retinal light signaling, intraocular cross‑tissue communication and scleral remodeling, with a focus on corneal biomechanics and the crosstalk between immunity and aging. It establishes an integrated analytical framework of “retinal phototransduction – trans-tissue cellular communication – scleral matrix remodeling”, from which three core mechanistic conclusions are drawn: 1) Myopia is a sterile, chronic low-grade inflammation driven by coordinated dysfunction of multiple ocular tissue cells; cellular senescence and localized inflammation form a positive feedback loop that continuously fuels excessive axial elongation. 2) Retinal glial cells and retinal pigment epithelium serve as relays for visual growth signals. Abnormal defocus disrupts their secretion of cytokines, breaking the homeostasis of scleral collagen synthesis and degradation. 3) The hypoxic microenvironment of the choroid can amplify scleral remodeling and exacerbate myopia progression. Integrating the multilayered signaling regulatory network formed by cells of the cornea, retina and sclera helps clarify the complete pathological logic underlying multicellular synergistic pathogenesis of myopia. It provides mechanistic evidence for the clinical development of an early myopia warning system, tissue-specific targeted pharmaceuticals and stratified individualized prevention and control regimens, and facilitates the shift of myopia intervention from conventional empirical management to a novel precision diagnosis and treatment paradigm grounded in cellular and molecular characteristics. Introduction Myopia has witnessed a continuous and sharp global rise in prevalence, evolving into a worldwide public health crisis. Predictions from a recent meta‑analysis show that the global prevalence of myopia has risen continuously from 24.32% in 1990 to 35.81% during 2020‑2023, and is projected to reach 39.80% by 2050. By then, the number of affected children and adolescents worldwide will exceed 740 million, and the myopia prevalence among adolescents aged 13‑19 years may reach 52.38%.1 High myopia triggers abnormal axial elongation and induces irreversible posterior segment lesions including retinal detachment, macular degeneration, and optic neuropathy. As one of the leading blinding ocular diseases globally, it imposes a heavy disease burden on individuals, families and societies.2 Current mainstream clinical myopia control interventions are merely symptomatic with limited precision. The core bottleneck lies in conspicuous gaps in existing research on pathogenic mechanisms, which fail to underpin the development of targeted, precise prevention and treatment technologies. Traditional myopia research has predominantly focused on macroscopic levels. Epidemiological surveys and family-based studies have validated the central roles of genetic susceptibility and environmental risk factors. Via Genome-Wide Association Study (GWAS) and multi-omics integrative analyses, multiple myopia susceptibility genes linked to axial growth and retinal function regulation, such as PRMT6, GATS and SH3YL1, have been identified.3 Meanwhile, environmental triggers critical to myopia onset and progression have been confirmed, including aberrant visual signals induced by near-work and diminished dopamine (DA) secretion resulting from insufficient outdoor activity.4 Nevertheless, such macroscopic research only establishes correlations between risk factors and cannot elaborate the microscale essence by which internal and external stimuli disrupt intraocular tissue function and drive myopia progression, presenting prominent research limitations. To systematically summarize advances in research on the cell biological mechanisms of myopia and fill existing knowledge gaps, this study retrieved and systematically sorted literature concerning cellular and molecular mechanisms of myopia published in PubMed and Web of Science from database inception to January 2026. Combined subject heading search strategies were adopted: ① myopia AND cell; ② myopia AND retina; ③ myopia AND sclera; ④ myopia AND cornea; ⑤ myopia AND choroid; ⑥ myopia AND signaling pathway; ⑦ myopia AND mechanism; ⑧ myopia AND therapy. No restrictions were imposed on the original publication language. Only original experimental articles and review papers investigating the cellular and molecular mechanisms of myopia were incorporated. A total of 320 articles were initially screened. After deduplication, preliminary screening based on titles and abstracts, and full‑text re‑screening, 111 articles were finally included for inductive analysis. This review only searched the two mainstream academic databases mentioned above and did not retrieve grey literature. Therefore, some relevant studies not indexed in these two databases may have been omitted, resulting in certain retrieval limitations. Centered on microscale cellular mechanisms underlying myopia pathogenesis, this review elaborates six dimensions: key ocular pathogenic cell subtypes, intercellular communication regulatory networks, core signaling cascades, early-stage biomarkers, targeted therapeutic targets, and future research directions. It aims to systematically integrate existing research findings, clarify the closed-loop cellular and molecular regulatory cascade driving myopia development, provide theoretical references for developing early diagnostic biomarkers, precise targeted preventive pharmaceuticals and gene therapy techniques for myopia, and facilitate the transition of myopia management from conventional symptomatic intervention to precise targeted therapy. The disease burden of myopia is not limited to ocular fundus complications. The high prevalence of myopia among adolescents can indirectly affect their schooling and career choices. The medical treatment for high‑degree myopia and vision‑correction consumables impose substantial economic costs on families and society. Accordingly, this issue is also worthy of attention in general practice. The core pathological processes summarized in this review, including cellular senescence, sterile low‑grade chronic inflammation, tissue hypoxia, and endoplasmic reticulum stress, are not eye‑specific. Instead, they represent common pathobiological pathways shared by multiple systemic diseases such as metabolic and degenerative disorders. Myopia can be regarded as a concrete manifestation of these universal cellular damage mechanisms in local ocular tissues. Meanwhile, the retina, one of the few neurovascular tissues accessible for non‑invasive observation in the human body, serves as an important window for monitoring systemic physiological and pathological conditions. Advances in ocular‑derived omics, as well as biomarkers in tears and aqueous humor, also suggest that ocular molecular features hold potential for expansion into systemic health screening. This extends the cellular and molecular research of myopia beyond the scope of specialized ophthalmology, and can provide a reference perspective for risk identification and population health management at the general practice level (Figure 1). Figure 1Cellular and Molecular Mechanisms of Myopia Development. Solid green arrows: Promote/increase target activity or abundance; Solid red arrows: Inhibit/decrease target activity or abundance; Solid black arrows: Neutral biological processes or state transitions; Dashed black arrows: Indirect signalling via unshown intermediates. Cell = rounded rectangle with internal nucleus dot; Receptor = square icon with ligand binding cleft; Secreted Factor/Ligand = light blue solid circle; Signal Molecule = pale purple circle.The diagram illustrates the mechanisms of myopia across three sections. The macroscopic view compares emmetropic and myopic eyes, highlighting normal versus elongated axial lengths. The tissue level zoom-in shows the retina, retinal pigment epithelium and sclera, detailing the ′Retina-Choroid-Sclera′ signaling cascade. Cellular and molecular mechanisms are divided into three focus areas: A) Retina, where dopamine and receptors are involved; B) Choroid, showing choroidal thinning and hypoxia; C) Scleral fibroblasts, detailing hypoxia effects, ECM homeostasis disruption and collagen synthesis. The integrated inter-tissue and cellular interaction network in myopia includes retinal neurons, RPE cells, choroidal vascular cells, scleral fibroblasts and corneal cells, with processes like dopamine reduction, ion transport impairment, reduced blood flow, ECM synthesis and cytokine mediation.Diagram of myopia mechanisms: macroscopic view, tissue level, cellular interactions. Cellular and Molecular Mechanisms of Myopia Development. Solid green arrows: Promote/increase target activity or abundance; Solid red arrows: Inhibit/decrease target activity or abundance; Solid black arrows: Neutral biological processes or state transitions; Dashed black arrows: Indirect signalling via unshown intermediates. Cell = rounded rectangle with internal nucleus dot; Receptor = square icon with ligand binding cleft; Secreted Factor/Ligand = light blue solid circle; Signal Molecule = pale purple circle. Cellular Biological Basis of Myopia Pathogenesis Association Between Key Intraocular Cell Types and Myopia Pathogenesis Role of Corneal Cells As the transparent anterior refractive tissue of the eyeball, the cornea constitutes a core component of the ocular refractive system. Its structural integrity and refractive stability rely on synergistic regulation by three cell populations: corneal epithelial cells, corneal stromal keratocytes and corneal endothelial cells.5 Existing studies have verified morphological, biophysical and molecular characteristic alterations in corneal cells under myopic conditions. However, academic consensus holds that the cornea is not a driver of axial elongation; these corneal changes are mostly secondary outcomes of axial lengthening and globe expansion. Whether abnormal corneal cell function actively participates in pathological myopia progression remains an unvalidated research hypothesis lacking universal consensus. Corneal endothelial cells are terminally differentiated with extremely weak proliferative capacity. Axial elongation accompanied by global ocular expansion increases total corneal inner surface area, forcing endothelial cells to flatten and spread to adapt to the enlarged inner surface. This process is accompanied by cytoskeleton rearrangement and downregulated expression of intercellular junction proteins, ultimately manifesting as reduced Endothelial Cell Density (ECD), a lower Hexagonal Cell Ratio (HEX), and an elevated Coefficient of Variation (COV) of cell area.6,7 The above morphological alterations are direct secondary consequences of mechanical tensile stress on the eyeball, capable of intuitively reflecting cumulative structural traction damage during myopia progression and holding potential as biomarkers for evaluating structural myopic injury.7 Findings from ZC3H11A heterozygous knockout mice and a cohort of 1015 Han adolescents with high myopia confirmed that aberrant biophysical properties of corneal stromal keratocytes and epithelial cells are closely correlated with hyperactivation of the phosphatidylinositol 3 kinase/protein kinase B (PI3K-AKT) and nuclear factor κB (NF-κB) signaling pathways,8 as well as suppressed F-actin and microtubule synthesis. Interventional experiments involving form-deprivation myopia (FDM) and lens-induced myopia (LIM) in White Leghorn chickens demonstrated that impaired F-actin and microtubule synthesis disrupts the regularity and stability of the cytoskeletal network, consequently reducing cellular stiffness, elevating cellular traction force and cell adhesion strength, and disrupting corneal mechanical homeostasis. Notably, these biophysical cellular alterations are reversible.5 In vitro corneal stromal lenticule assays on 38 patients undergoing SMILE surgery revealed profound metabolic dysregulation in the myopic corneal stroma. Key biochemical components including collagen, lipids and nucleic acids undergo characteristic shifts with increasing myopic diopters. Enhanced collagen degradation coupled with insufficient collagen synthesis weakens the structural supportive capacity of the stroma, while abnormal lipid accumulation and high apolipoprotein E (APOE) expression trigger membrane metabolic disorder and accumulation of pro-inflammatory precursors.9 Meanwhile, marked downregulation of mitochondrial energy metabolism proteins blocks oxidative phosphorylation, limits Adenosine Triphosphate (ATP) generation, and elevates risks of oxidative stress and ferroptosis, leading to corneal cellular energy depletion and impaired tissue repair.10 Cascade activation of the complement system is detectable in corneas of high myopia patients, with significant upregulation of complement components and active fragments such as C3, C5 and C8. These molecules accelerate local extracellular matrix (ECM) degradation in the cornea by inducing expression of matrix metalloproteinase 2 (MMP2) and plasminogen. Degraded ECM fragments in turn reactivate complement cascades, forming a self-amplifying positive feedback loop within the cornea. This synergistic reaction further suppresses mitochondrial function and exacerbates metabolic imbalance, ultimately inducing disorganized collagen arrangement, deteriorated corneal biomechanical properties and compromised structural stability — hallmark pathological alterations of the cornea under myopic conditions.9,10 The contributions of corneal cells to myopia pathogenesis are frequently underappreciated. Research value of corneal-related changes lies primarily in two aspects: first, the cornea acts as a “biomechanical window” for myopia progression; parameters such as corneal keratocyte stiffness and traction force dynamically reflect mechanical remodeling status of intraocular tissues via non-invasive detection, conferring high translational potential. Second, morphological changes of corneal endothelial cells constitute direct consequences of axial mechanical traction and can serve as biomarkers quantifying cumulative structural myopia damage. Current research remains limited to correlation descriptions, lacking experimental validation establishing causal relationships between corneal cellular dysfunction and the retina-sclera axis. Future studies must integrate biomechanical models and conditionally gene-edited animals to elucidate the independent contribution of corneal cells to refractive development. Role of Retinal-Related Cells As the core tissue responsible for sensing and processing visual signals, dysfunction of multiple intrinsic retinal cell populations is tightly linked to myopia onset and progression. Retinal Pigment Epithelium (RPE) Cells As critical barrier cells in the outer retina, Retinal Pigment Epithelium (RPE) cells not only execute fundamental physiological functions including maintaining retinal microenvironmental homeostasis and phagocytosing shed photoreceptor outer segments,11 but also serve as central mediators regulating intraocular refractive homeostasis and axial elongation. Functioning as a vital interface bridging the retina, choroid and sclera, RPE cells participate in myopia pathogenesis via two dual regulatory pathways. On one hand, they modulate choroidal thickness through ion and fluid transport to sustain dynamic intraocular refractive equilibrium. On the other hand, they relay retina-derived growth-regulatory signals to control proliferation and ECM synthesis of scleral fibroblasts (SFs), thereby governing axial length homeostasis.12 In terms of refractive homeostasis regulation, polar-distributed ion transport systems within RPE cells mediate material exchange between the subretinal space and choroid,13,14 which can be directly disrupted by abnormal visual environments. In monocular LIM chick models, suppressed Cl⁻ channel activity in RPE cells induces choroidal atrophy and thinning with posterior retinal displacement, laying an anatomical foundation for axial elongation. By contrast, myopic defocus activates fluid transport to trigger choroidal congestion and thickening, forming a protective mechanism restraining excessive axial growth.15 Regarding growth signal transduction, rhesus monkey interventional experiments indicated that neurotransmitters released by the retina upon visual stimulation — including DA, vasoactive intestinal peptide (VIP) and acetylcholine — bind specific surface receptors on RPE cells to remodel their growth factor secretome and indirectly modulate scleral remodeling. DA exerts protective effects against axial lengthening by activating D2 receptors on RPE cells to suppress secretion of factors promoting scleral chondrocyte proliferation and reduce scleral ECM synthesis.16 Combined interventional experiments in chicks and guinea pigs alongside in vitro human RPE cell assays indicated that VIP elevates intracellular cyclic adenosine monophosphate (cAMP) levels in RPE cells to boost secretion of pro-growth factors, driving scleral proliferation and axial elongation.17 Additionally, in rigid contact lens-induced myopia models of pigmented New Zealand guinea pigs, significant downregulation of growth-suppressive genes Bmp2 and Id3 was observed within RPE cells, while microRNAs such as miR-328 and miR-29a mediate cascade transmission of myopia-associated regulatory signals.12,18 FDM experiments in C57BL/6 mice paired with in vitro mouse RPE cultures demonstrated that DA-circadian rhythm signaling governs RPE phagocytosis of photoreceptor outer segments. Reduced DA secretion under myopic conditions directly impairs RPE phagocytic activity, leading to rarefied choroidal capillaries and insufficient blood perfusion, which indirectly accelerates scleral collagen matrix remodeling and axial elongation.12 Axial length exhibits a significant negative correlation with RPE cell density. Abnormal bulging of RPE cells in high myopia patients may trigger severe complications such as choroidal neovascularization.19–21 RPE cells also function as core effector cells mediating myopia-related inflammatory responses. In hamster monocular FDM myopia models, robust upregulation of pro-inflammatory cytokines (tumor necrosis factor α [TNF-α], interleukin 6 [IL-6], interleukin 1β [IL-1β]) was detected within the RPE layer. Resveratrol intervention inhibits expression of these pro-inflammatory factors and simultaneously mitigates axial elongation.22 Oxidative stress imbalance in the aqueous humor of high myopia patients generates excess reactive oxygen species that directly damage RPE structure, while accelerating scleral matrix degradation and myopia progression via remodeling growth factor networks and activating inflammatory cascades.23 Retinal Ganglion Cells (RGCs) Retinal ganglion cells (RGCs) are pivotal neurons transmitting visual signals to the visual cortex. Disruption of their structural integrity and functional homeostasis contributes to myopia onset and deterioration.24 Structurally, diffuse pan-retinal reduction in RGC density accompanies synchronous thinning of the retinal nerve fiber layer and ganglion cell-inner plexiform layer (GC-IPL) under myopic conditions.25,26 Clinical studies revealed that GC-IPL thickness declines far more rapidly in elderly high myopia patients than younger counterparts, indicating synergistic damage to RGC-associated structures driven by age and myopia severity.27 Interventional experiments in C57BL/6 mice, Opn4-knockout mice and chemogenetically modified rodents functionally indicated that intrinsically photosensitive retinal ganglion cells (ipRGCs) govern ocular refractive development and intraocular tissue remodeling via melanopsin-mediated phototransduction cascades; melanopsin is encoded by the Opn4 gene. Activation and ablation of ipRGCs induce hyperopic and myopic refractive shifts, respectively.28 Melanopsin signaling directly perceives light stimuli to promote axial elongation: Opn4-knockout mice display markedly shortened axial lengths, whereas mice retaining intact melanopsin signaling develop longer eyes under illumination, confirming this pathway as a positive driver of axial growth.28 Furthermore, rod and cone photoreceptors modulate ipRGC activity via synaptic input to finely regulate corneal curvature. Under melanopsin deficiency, ipRGC ablation induces steepened corneas (reduced corneal radius of curvature), while intact rod/cone signaling preserves physiological corneal curvature. M1-subtype ipRGCs participate in corneal developmental regulation through retrograde signaling with dopaminergic amacrine cells.28 Collectively, melanopsin-dependent axial regulatory cascades and rod/cone-dependent corneal regulatory pathways exert distinct, complementary roles in myopia. Dysfunctional ipRGCs also indirectly disrupt axial growth equilibrium by altering retinal DA release.28 At the molecular level, dysregulation of competing endogenous RNA (ceRNA) networks in RGCs (exemplified by the lncRNA-XR_002792574.1/miR-760-3p/Adcy1 regulatory axis) induces RGC injury via suppression of cyclic guanosine monophosphate/protein kinase G (cGMP/PKG) and apelin signaling, consequently activating the extracellular regulated protein kinases-MMP2 (ERK-MMP2) cascade to drive scleral remodeling. This regulatory logic has been fully validated in pigmented guinea pig and C57BL/6 FDM animal models, as well as cross-sectional ocular tissue samples from adult high myopia patients.25 Common marmoset LIM assays demonstrated progressive deterioration of RGC function alongside myopia advancement: excessive axial stretching mechanically pulls the retina, compromises blood supply and disrupts the local microenvironment to damage RGC structure and signal transduction, reflected by continuous attenuation of photopic negative response (PhNR) amplitude—a functional readout of RGC activity. Impaired RGCs lose their negative feedback inhibition on axial elongation, failing to restrain excessive globe expansion while disrupting retinal neural circuits to further exacerbate axial lengthening and myopia severity.24 Structural damage and functional impairment of RGCs establish a vicious cycle that perpetuates retinal-choroidal-scleral pathological lesions, driving progressive myopia and elevating the risk of posterior segment complications. Astrocytes, Müller Glia and Microglia Astrocytes and Müller glia constitute the primary subpopulations of retinal glial cells, and their functional dysregulation acts as a key driver of abnormal axial elongation and retinal structural remodeling.29 Sustained defocus markedly amplifies the myopigenic effects of astrocytes: alongside reduced cellular counts, enhanced glial fibrillary acidic protein (GFAP) immunoreactivity triggers retinal nerve fiber layer (RNFL) thinning. The physiological coordinated balance between astrocyte proliferation and retinal layer thickening during ocular growth is disrupted, directly accelerating myopia progression.30,31 Assays in C57BL/6 mouse FDM models revealed co-activation of astrocytes and Müller glia, manifested by upregulated GFAP and excitatory amino acid transporter 4 (EAAT4) expression.29 Activated glia precisely sense microenvironmental perturbations such as hypoxia, constructing signaling bridges between retinal vasculature and neurons via secretion of bioactive factors that transmit regulatory signals to the sclera and trigger scleral remodeling. Their activation cascades overlap extensively with the molecular targets of atropine, suggesting retinal glia as promising core targets for myopia modulation.29 The unique regulatory functions of Müller glia manifest prominently at the molecular level: PRSS56, a secreted serine protease derived specifically from Müller glia, exerts decisive control over axial elongation.32 Series of gene‑editing intervention experiments in C57BL/6 mice indicate that sustained activity of this protease persists throughout critical ocular developmental stages and serves as a core safeguard for maintaining normal refractive status. Complete germline loss‑of‑function abolishes the gene’s pro‑ocular‑growth effect entirely, resulting in insufficient axial development, shortened axial length and induced hyperopia. By contrast, in the pathological model of excessive axial elongation mediated by abnormal PRSS56 overexpression, suppressing PRSS56 gene expression can reverse the pathological phenotype of excessive axial elongation.32 Microglia and Müller glia represent the major intraretinal immunomodulatory populations, critical to maintaining retinal microenvironmental homeostasis.24,33 As resident retinal innate immune cells, microglia undergo activation in response to myopia-induced retinal microenvironmental shifts, transitioning from ramified resting morphology to amoeboid activated phenotypes and releasing pro-inflammatory mediators including IL-1β and TNF-α to exacerbate retinal inflammatory responses.34,35 Combined ex vivo retinal tissue assays and primary Müller glia in vitro cultures from mice, rabbits and guinea pigs indicated that Müller glia sustain neuronal function by balancing extracellular ion concentrations and secreting neurotrophic factors.36 Through morphological remodeling, molecular signal secretion and immune-inflammatory regulation, astrocytes, Müller glia and microglia collectively form a core regulatory network governing myopia onset and progression. Their functional equilibrium and subtype-specific molecular mechanisms provide critical theoretical support and prospective target directions for targeted myopia interventions. Cone Photoreceptors As primary photoreceptors mediating photopic vision and color perception, dysfunctional visual signal detection by cone cells serves as an essential initiating trigger for myopia induction.12 A human cross-sectional study enrolling 43 patients with isolated high myopia and 38 age-matched healthy controls demonstrated progressive cone density reduction, enlarged intercellular spacing, disrupted spatial distribution regularity and diffuse pan-retinal degeneration during high myopia pathogenesis, destabilizing native retinal structural homeostasis.37 Multiple genetic interventional assays using GNAT2-knockout mice demonstrated that cone dysfunction impairs light signal reception and processing, disrupting negative feedback loops restraining axial elongation and promoting excessive ocular lengthening.38 Furthermore, thinning of the cone ellipsoid zone (EZ) correlates strongly with diminished retinal sensitivity, aggravating vision impairment associated with myopia. Prospective clinical cross-sectional observations combining multimodal fundus imaging and microperimetry across emmetropic, low, moderate and high myopia adults confirmed EZ (myoid-ellipsoid band) thickness as a robust predictive biomarker of retinal sensitivity.39 Cone cells also modulate DA secretion to attenuate DA-mediated suppression of axial elongation.40,41 Synthesized evidence from adult twin cohort cross-sectional studies, human retinal single-cell transcriptomics and clinical electroretinogram (ERG) functional testing established that cone-driven OFF-bipolar cell signaling cascades correlate closely with myopia susceptibility. The GJD2 gene (encoding connexin 36 [Cx36]) is highly expressed in cone cells and OFF-bipolar cells; genetic polymorphisms of GJD2 significantly elevate individual myopia risk by altering signal transduction efficiency within these pathways.42 Cone-mediated retina-sclera signaling axes regulate scleral remodeling, and cone dysfunction indirectly disrupts scleral metabolic homeostasis via paracrine release of bioactive factors to drive myopia progression.43 Genetic variants in cone-specific genes directly increase myopia risk. For instance, human genetic association cross-sectional studies in European adult males combined with in vitro HEK293T splicing functional assays confirmed strong correlations between high myopia and mutations in OPN1LW/OPN1MW and ARR3.44,45 GNAT2-mutant mice with intrinsic cone dysfunction exhibit drastically heightened susceptibility to FDM.46 Patients with RPGR-related retinal dystrophy display a prominent correlation between early-onset cone degeneration and high myopia, implying that degraded visual input from childhood cone dysfunction acts as a key pathological stimulus driving myopia development.47 Individuals with red-green color deficiency—rooted in subtype-specific cone dysfunction—exhibit markedly lower myopia prevalence and shorter axial lengths, further corroborating the involvement of intact cone physiological function in myopia pathogenesis.48 Interactive effects between cone cells and environmental stimuli govern myopia progression, with distinct regulatory outcomes induced by varying light wavelengths via cone-mediated signaling. Short-wavelength light (blue, violet) suppresses axial elongation through activation of cone-dependent cascades,49–51 whereas regulatory effects of long-wavelength light (red) exhibit species-specific variability and modulate myopia via altering cone activity.52,53 Cone-mediated myopia regulation is more pronounced under low-intensity, low-frequency illumination, while high-intensity light attenuates these protective effects, demonstrating that environmental lighting parameters shape myopia progression via modulating cone function.40,54 Cone loss significantly exacerbates myopia severity; cones coordinate with rods to jointly transduce visual signals and mediate adaptive axial growth in response to environmental visual stimuli.46 The retina is not merely a passive terminal tissue receiving visual input, but a central regulatory hub actively governing ocular refractive development via multicellular coordination. The field has established well-validated, cross-model consensus mechanisms defining independent functions of individual retinal cell subtypes, each with distinct, stable specialized roles in refractive regulation: RPE cells function as the central intraocular “metabolism-inflammation” regulatory node; compromised barrier integrity and disrupted material transport represent upstream initiating events driving choroidal thinning and interrupted intraocular signal transmission; RGCs (especially ipRGCs) execute “light-growth” signal conversion, sensing ambient light fluctuations and encoding them as neuroendocrine signals to precisely modulate axial elongation; Müller glia, astrocytes and microglia collectively constitute the retinal “immune-homeostasis” regulatory network; their aberrant activation sustains the chronic low-grade inflammatory microenvironment characteristic of myopia; Cone cells serve as primary sensory initiators of visual signal transduction; their dysfunction generates aberrant visual input, the foundational trigger of myopia onset. In stark contrast to well-elucidated single-cell functional mechanisms, substantial unresolved controversies persist regarding spatiotemporal multicellular coordination networks within the retina, which remain in early exploratory stages without unified consensus. First, the sequential interaction and upstream-downstream relationships between distinct cell populations remain uncharacterized. A representative unresolved debate concerns the causal order of glial activation and RPE inflammatory injury, lacking time-series experimental evidence delineating their temporal sequence of action. Second, most existing research conclusions derive from acute high-intensity animal models such as FDM, which deviate drastically from the chronic, mild, progressive natural course of pediatric and adolescent human myopia, limiting clinical translatability of basic experimental findings. Future research must deploy cutting-edge technologies including conditional gene knockout and dynamic single-cell lineage tracing to construct preclinical models recapitulating human myopia progression, precisely dissect time-dependent regulatory roles of each retinal cell subtype during refractive error development, and clarify the complete multicellular synergistic pathogenic cascade. Role of Scleral-Related Cells As the fibrous outer tissue of the eyeball, the sclera is primarily composed of SFs and ECM. Its structural integrity and biomechanical stability directly determine globe morphology and axial length.55 SFs represent the principal functional cell population of the sclera, synthesizing and secreting ECM components including collagens and elastin to maintain scleral thickness and stiffness.56 Pathogenic triggers including hypoxic microenvironments, form deprivation and aberrant visual signals converge on SFs to disrupt dynamic equilibrium of proliferation, apoptosis and differentiation. This imbalance destabilizes ECM synthesis-degradation homeostasis, amplifies pathological scleral remodeling through multiple intersecting signaling cascades, and ultimately drives myopia progression.57 FDM assays in mice paired with in vitro hypoxic culture of human scleral fibroblasts (HSFs) revealed that hypoxia upregulates Adamts1 and Adamts5 expression in HSFs. The metalloproteinases encoded by these genes selectively degrade core ECM constituents such as type I collagen (Col I), inducing hyperactive catabolism of scleral ECM and compromising scleral structural integrity.58 Concurrently, the hypoxia-inducible factor 1α (HIF-1α) cascade promotes transdifferentiation of fibroblasts into myofibroblasts, upregulating expression of genes governing ECM remodeling and exacerbating scleral thinning.59 The FOXM1-METTL3-APOA1 regulatory axis synergizes with hypoxic signaling to epigenetically suppress ECM synthetic capacity of SFs, further amplifying scleral remodeling.60 SFs dysfunction is regulated across multiple dimensions. Combined LIM/FDM interventional assays in SD rats and in vitro hypoxic genetic manipulation of primary rat SFs demonstrated that downregulation of Mfn2 disrupts endoplasmic reticulum homeostasis, triggers ER stress, facilitates fibroblast transdifferentiation and suppresses collagen secretion. Overexpression of Mfn2 reverses hypoxia-induced pathological alterations.61 In terms of non-coding RNA regulation, combined in vivo guinea pig modeling and in vitro HSFs functional experiments suggested miR-29a as a novel regulatory molecule that activates downstream inflammatory cascades via direct binding to Toll-like receptor 7/8 (TLR7/8) and specifically inhibits transcription and expression of COL1A1 (encoding Col I α1 chain), reducing Col I biosynthesis.62 Cross-sectional clinical tissue analysis of human high myopia samples, in vitro genetic manipulation of HSFs and dual-luciferase reporter assays collectively suggested that hsa-miR-142-3p targets the 3’ untranslated region (3’UTR) of transforming growth factor β1 (TGF-β1) to suppress TGF-β1 expression and indirectly reduce Col I synthesis efficiency. Its aqueous humor expression level correlates positively with axial length, marking hsa-miR-142-3p as a prospective molecular biomarker and therapeutic target for myopia progression.63 Combined interventional assays in C57BL/6 knockout mice and pigmented guinea pigs alongside in vitro pharmaceutical intervention of HSFs showed that reduced phosphodiesterase 4B (PDE4B) activity disrupts intracellular cAMP homeostasis to further suppress scleral collagen synthesis. This mechanism synergizes with previously described pathways to exacerbate disorganized scleral ECM architecture.64 Two fibroblast subpopulations characterized by high EFEMP1 and high Wnt5a (Wnt5ahi) expression exert pivotal regulatory effects during SF-mediated myopia progression. EFEMP1 expression is markedly elevated in the sclera of FDM models. It activates the PI3K/AKT/MMP2 signaling axis to drastically upregulate MMP2 while suppressing secretion of Col I and aggrecan (ACAN), accelerating ECM degradation and thinning of scleral collagen fibrils. Targeted suppression of EFEMP1 effectively retards myopia progression, identifying EFEMP1 as a promising therapeutic candidate for myopia control.65 Wnt5ahi fibroblasts predominantly localize to the posterior scleral pole—the region exhibiting the most severe structural remodeling in myopia. This subpopulation is drastically depleted in myopia models, with depletion severity paralleling myopia advancement. Wnt5ahi fibroblasts maintain physiological COL1A1 expression and stable collagen fibril diameter via downstream regulation of Sparc and non-canonical Wnt-Ca2⁺/calmodulin-dependent kinase II (Wnt/CaMKII) signaling cascades. Depletion of this subpopulation directly destabilizes ECM homeostasis to drive myopia, while exogenous Wnt5a supplementation partially reverses pathological remodeling, demonstrating high specificity for myopia regulation.56 SFs function is additionally modulated by immune cells and metabolic factors, forming a multi-factor intersecting regulatory network. Triple-system validation integrating mouse gene-edited modeling, in vitro functional verification of human-derived cells and clinical tissue testing of myopia patients confirmed that macrophage extracellular traps (METs) directly trigger transdifferentiation of SFs into myofibroblasts, inhibit COL1A1 secretion and promote SFs apoptosis. Hypoxia and activated platelets amplify MET release by inducing macrophage autophagy, establishing a sequential regulatory axis: hypoxia-platelet activation-macrophage activation-MET release-fibroblast dysfunction, which further amplifies pathological scleral remodeling. Knockout of core genes governing MET biogenesis or administration of MET inhibitors (eg, lactoferrin) effectively suppress myopia progression, highlighting METs as innovative therapeutic targets for myopia management.66 Combined LIM interventional assays in pigmented guinea pigs and in vitro amino acid manipulation of primary guinea pig SFs delineated metabolic regulatory mechanisms: deficiency of amino acids such as glycine directly diminishes COL1A1 synthesis in SFs while suppressing glutathione (GSH) production to weaken cellular antioxidant capacity. This triggers downregulation of ferroptosis-associated proteins glutathione peroxidase 4 (GPX4) and ferritin heavy chain 1 (FTH1), exacerbating insufficient ECM synthesis and scleral tissue damage. Exogenous glycine supplementation reverses these pathological alterations by inhibiting SFs ferroptosis, providing an entirely novel metabolic intervention strategy for myopia control.67 SFs have been redefined from passive ECM maintainers to “executors of the final common pathway” mediating myopic pathology. Exposed to cumulative insults including hypoxia, inflammation and mechanical strain, fibroblasts shift from a synthetic resting state to a pathological phenotype dominated by ECM degradation and transdifferentiation. This phenotypic transition integrates multiple regulatory mechanisms: HIF-1α-mediated hypoxic responses, EFEMP1/PI3K/AKT-driven hyperactive matrix degradation, ECM synthetic insufficiency induced by depletion of Wnt5ahi subpopulations, and emerging pathways including MET release and ferroptosis. Glycine metabolism and ferroptosis mechanisms establish a direct link between scleral remodeling and cellular metabolic reprogramming, delivering an unprecedented framework for developing metabolic intervention strategies. Future research priorities include: Identification of master switch molecules (transcription factors or epigenetic regulators) driving fibroblast phenotypic transformation; Elucidation of how disparate pathological stimuli (hypoxia, inflammation, mechanical tension) converge on shared cellular effector cascades; Development of interventions capable of reversing rather than merely delaying pathological fibroblast phenotype switching. Subtype heterogeneity of SFs (epitomized by the Wnt5ahi population) unlocks opportunities for precise targeted therapy, yet comprehensive functional validation of distinct fibroblast subpopulations remains necessary (Table 1). Table 1Key Ocular Cells in MyopiaSpecific Cell TypeCore Functional AbnormalityDownstream Effects on Axial ElongationEvidence LevelCorneal cellsCorneal endothelial cellsFlattening from traction, decreased density, disrupted intercellular junctions6,7Secondary change; does not directly drive axial growthLevel I (pediatric/adult cross-sectional)Corneal cellsCorneal stromal keratocytes/epithelial cellsPI3K-AKT/NF-κB activation,8 cytoskeleton disruption,5 oxidative stress,10 complement activation,9,10 collagen degradation9Reduced biomechanical strength; amplifies mechanical stress; indirectly aggravates scleral ECM degradationLevel II (primary human corneal cells / tissue transcriptomics)Retinal pigment epitheliumRPE cellsImbalanced ion transport,15 pro-inflammatory cytokine release,22 impaired DA-D2 pathway,16 reduced phagocytosis12Choroidal hypoxia; VIP secretion suppresses collagen synthesis and accelerates ECM degradation; inflammatory signal relay and amplificationLevel II (multi-species + human RPE in vitro; Level I: aqueous humor in high myopia)Retinal neuronsipRGCs/RGCsDysregulated melanopsin pathway,28 GC-IPL thinning,27 ceRNA dysregulation,25 trans-synaptic degeneration28Encodes light-driven growth signals; weakens negative feedback on collagen synthesis; activates MMP to exacerbate ECM degradationLevel II (knockout mice, marmosets; Level I: fundus imaging)Retinal gliaMüller gliaDysregulated PRSS56 secretion,32 glial activation,34,35 ion imbalance36PRSS56 disrupts inner limiting membrane ECM homeostasisLevel II (gene-edited mice + human single-cell)Retinal gliaAstrocytes/microgliaIncreased GFAP,29 pro-inflammatory cytokine release, immune cell recruitment30,31Chronic low-grade inflammatory microenvironment; activates scleral NF-κB; upregulates MMP2 to accelerate ECM degradationLevel II (mouse FDM + ex vivo retina)Retinal photoreceptorsCone photoreceptorsDisrupted phototransduction,38 reduced density,37 abnormal OFF-bipolar pathway,42 impaired DA regulation40,41Upstream initiator; triggers retina-sclera signaling cascadeLevel II (knockout mice + human ERG)Scleral effector cellsSFsSubset depletion,56 activation of hypoxia/inflammatory pathways,58–63 MET-induced transdifferentiation66Reduced collagen synthesis, extensive collagen degradation, decreased scleral stiffnessLevel II + I (multi-species animal models + human primary scleral cells)Immune infiltrating cellsMacrophages/γδ T cells/NKT cellsActivated release of METs66 and SASP pro-inflammatory factors68,69Senescence-immune positive feedback; stimulates SF transdifferentiation; inhibits collagen synthesis and promotes ECM degradationLevel II (mouse gene-edited models + primary human SFs in vitro) Table 1Key Ocular Cells in MyopiaSpecific Cell TypeCore Functional AbnormalityDownstream Effects on Axial ElongationEvidence LevelCorneal cellsCorneal endothelial cellsFlattening from traction, decreased density, disrupted intercellular junctions6,7Secondary change; does not directly drive axial growthLevel I (pediatric/adult cross-sectional)Corneal cellsCorneal stromal keratocytes/epithelial cellsPI3K-AKT/NF-κB activation,8 cytoskeleton disruption,5 oxidative stress,10 complement activation,9,10 collagen degradation9Reduced biomechanical strength; amplifies mechanical stress; indirectly aggravates scleral ECM degradationLevel II (primary human corneal cells / tissue transcriptomics)Retinal pigment epitheliumRPE cellsImbalanced ion transport,15 pro-inflammatory cytokine release,22 impaired DA-D2 pathway,16 reduced phagocytosis12Choroidal hypoxia; VIP secretion suppresses collagen synthesis and accelerates ECM degradation; inflammatory signal relay and amplificationLevel II (multi-species + human RPE in vitro; Level I: aqueous humor in high myopia)Retinal neuronsipRGCs/RGCsDysregulated melanopsin pathway,28 GC-IPL thinning,27 ceRNA dysregulation,25 trans-synaptic degeneration28Encodes light-driven growth signals; weakens negative feedback on collagen synthesis; activates MMP to exacerbate ECM degradationLevel II (knockout mice, marmosets; Level I: fundus imaging)Retinal gliaMüller gliaDysregulated PRSS56 secretion,32 glial activation,34,35 ion imbalance36PRSS56 disrupts inner limiting membrane ECM homeostasisLevel II (gene-edited mice + human single-cell)Retinal gliaAstrocytes/microgliaIncreased GFAP,29 pro-inflammatory cytokine release, immune cell recruitment30,31Chronic low-grade inflammatory microenvironment; activates scleral NF-κB; upregulates MMP2 to accelerate ECM degradationLevel II (mouse FDM + ex vivo retina)Retinal photoreceptorsCone photoreceptorsDisrupted phototransduction,38 reduced density,37 abnormal OFF-bipolar pathway,42 impaired DA regulation40,41Upstream initiator; triggers retina-sclera signaling cascadeLevel II (knockout mice + human ERG)Scleral effector cellsSFsSubset depletion,56 activation of hypoxia/inflammatory pathways,58–63 MET-induced transdifferentiation66Reduced collagen synthesis, extensive collagen degradation, decreased scleral stiffnessLevel II + I (multi-species animal models + human primary scleral cells)Immune infiltrating cellsMacrophages/γδ T cells/NKT cellsActivated release of METs66 and SASP pro-inflammatory factors68,69Senescence-immune positive feedback; stimulates SF transdifferentiation; inhibits collagen synthesis and promotes ECM degradationLevel II (mouse gene-edited models + primary human SFs in vitro) Key Ocular Cells in Myopia Core Cellular Signaling Pathways in Myopia Pathogenesis Inflammatory and Immune-Related Pathways Inflammatory and immune cascades revolve around multicellular coordinated responses, ultimately driving myopia progression via regulation of ECM remodeling.70 The NF-κB pathway constitutes the central inflammatory regulatory axis: membrane attack complex C5b-9 generated upon complement system activation initiates NF-κB cascades in SFs and retinal glia, stimulating secretion of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. Paracrine signaling upregulates MMP-2 expression in SFs to selectively degrade Col I, inducing scleral thinning and globe expansion.71,72 Mitogen-activated protein kinase (MAPK) cascades mediate transmission of inflammatory signals across the ocular surface and intraocular tissues: inflammatory stimuli at the ocular surface propagate through MAPK signaling to RGCs, choroidal endothelial cells and retinal microglia.73,74 On one hand, MAPK amplifies inflammatory cascades and elevates vascular permeability; on the other hand, it directly modulates SFs function via phosphorylation-mediated activation of activator protein 1 (AP-1), upregulating MMP-2 while suppressing collagen synthesis.74,75 MAPK further synergistically activates NF-κB through IκB phosphorylation, establishing a vicious cycle compounded by hypoxia induced by axial elongation.73 Toll-like receptors and the complement system coordinate immune cell recruitment: TLR receptors on RPE cells and microglia detect tissue damage signals to activate downstream inflammatory cascades and promote macrophage infiltration into the sclera. Beyond generating C5b-9 to trigger NF-κB signaling, complement activation within the retina and choroid releases anaphylatoxins such as C3a and C5a to recruit immune cell aggregation and further activate SFs.74,75 The TGF-β pathway exhibits dual functional duality: it initiates pro-inflammatory programs via the transforming growth factor β-activated kinase 1-IκB kinase-NF-κB (TAK1-IKK-NF-κB) axis to upregulate MMP-2 and accelerate scleral degradation, while simultaneously promoting ECM synthesis and preserving scleral homeostasis through the SMAD2/3 cascade. Its functional outcome is entirely context-dependent on the local microenvironment.76 SMAD7 acts as a negative feedback modulator to counterbalance excessive TGF-β activation, yet cannot fully offset signal amplification driven by inflammation.76 Contemporary research has shifted focus from verifying the existence of myopia-associated inflammation to delineating its initiation and maintenance mechanisms. Complement-derived C5b-9 directly activates NF-κB signaling in SFs, establishing a direct molecular connection between immune effectors and scleral target cells. Synergistic crosstalk between MAPK and NF-κB creates a self-amplifying inflammatory feedback loop, while the dual functionality of TGF-β underscores context-dependent pathway activity. Intraocular inflammation linked to myopia is not classical infectious or autoimmune inflammation, but rather “mechanical-metabolic inflammation” driven by abnormal mechanical traction and hypoxic microenvironments—essentially a sterile, low-grade chronic tissue stress response. This mechanistic classification guides rational anti-inflammatory therapeutic design: systemic immunosuppression is likely unnecessary, whereas targeted inhibition of mechanosensitive ion channels or hypoxia sensors (eg, HIF-1α) enables far more precise intervention. Cellular Senescence-Related Pathways Cellular senescence pathways participate in myopia progression primarily via the TP53-CDKN1A-MYC regulatory network and senescence-associated secretory phenotype (SASP). Hypoxia and mechanical traction upregulate TP53 expression in ARPE-19 cells and retinal cells of C57BL/6 mice to elevate p53 protein levels. p53 transcriptionally activates CDKN1A, whose encoded p21 protein suppresses cyclin-dependent kinase activity to induce cell cycle arrest.68,69 Concurrently, p53 represses MYC expression to further diminish cellular proliferative capacity and trigger senescence.77 Senescence impairs functional performance of retinal cells and SFs, disrupting tissue homeostasis and facilitating myopia progression. SASP factors secreted by senescent cells—including IL-6 and MMP-2—exert paracrine effects to exacerbate local inflammation and remodel ECM in neighboring cells, establishing a vicious “senescence-inflammation-tissue damage” cycle that perpetuates myopia advancement.58,68 Integration of cellular senescence into myopia pathogenic research represents a landmark paradigm shift. Historically, cellular senescence was primarily associated with malignancies and degenerative disorders. However, evidence compiled within this review demonstrates that retinal and scleral cells enter senescence under the hypoxic and mechanically stressed microenvironments of myopia, amplifying local inflammation and tissue damage via SASP. Senescence observed in myopia constitutes stress-induced premature senescence rather than replicative senescence, indicating that sustained pathological stimuli can activate senescence programs even in juvenile ocular tissues. This unlocks a novel therapeutic window: senolytic agents (eg, quercetin, dasatinib) or SASP inhibitors hold promise as innovative myopia treatments.78 Critical safety caveats apply: long-term suppression or knockout of the core tumor suppressor TP53 (via CRISPR/Cas9 for instance) may elevate oncogenic risk. Accordingly, senescence-targeted myopia interventions must prioritize localized, reversible, transient regulation rather than systemic or permanent genome editing. Endoplasmic Reticulum Stress Pathway ER stress drives myopia pathogenesis via activation of three core axes: inositol-requiring enzyme 1-X-box binding protein 1 (IRE1-XBP1), protein kinase R-like ER kinase-eIF2α (PERK-eIF2α), and activating transcription factor 6 (ATF6). Combined LIM interventional assays in C57BL/6 mice and White Leghorn chickens alongside in vitro HSF cultures localized the primary pathogenic effects of ER stress to SFs. The PERK-eIF2α cascade phosphorylates eIF2α to globally suppress protein synthesis and disrupt expression of collagen isoforms including COL1A1, while the ATF6 cascade maintains cellular functional homeostasis via transcriptional regulation of collagen genes. Synergistic activation of both cascades induces scleral collagen fibril thinning and destabilized ECM remodeling to drive axial elongation.79 Although activated, the IRE1-XBP1 axis plays a secondary, non-dominant role.79 FDM interventional assays in pigmented guinea pigs paired with HSF in vitro experiments further revealed that ER stress modulates protein-protein interactions between glucose-regulated protein 78-acyl-CoA synthetase long-chain family member 4/glutathione peroxidase 4 (GRP78-ACSL4/GPX4) to inhibit ferroptosis,80 while Mfn2-mediated ER-mitochondrial homeostasis suppresses SFs transdifferentiation and apoptosis.61 ER stress inhibitors such as 4-phenylbutyric acid (4-PBA) reverse pathological scleral remodeling and suppress myopia progression by blocking these cascades.81 ER stress acts as a pivotal molecular bridge linking environmental stimuli to cellular dysfunction, exhibiting dose-dependent biphasic effects: mild stress initiates the unfolded protein response to restore homeostasis, whereas severe or persistent stress triggers apoptotic or senescence programs. Myopia is characterized by chronic sublethal ER stress that merely impairs cellular function, rendering this pathway an ideal pharmacological target. Moderate alleviation of ER stress via small-molecule chemical chaperones (eg, 4-PBA) or natural phytochemicals (eg, quercetin) restores cellular equilibrium without complete pathway inhibition. Extensive crosstalk exists between ER stress, inflammation and senescence (for example, PERK-eIF2α signaling activates NF-κB), highlighting the need to develop multi-target modulators simultaneously targeting multiple pathway nodes for future therapeutic development. Genetic and Environmental Interactions at the Cellular Biological Level Myopia arises from synergistic gene-environment interactions, which functionally converge via intraocular cell function and signaling cascades. Genetic susceptibility genes establish cellular response thresholds to environmental stimuli. PRSS56, encoding serine protease 56, is expressed within Müller glia and governs axial development by stabilizing ECM homeostasis of the inner limiting membrane; PRSS56 dysfunction drives excessive axial elongation.32 Combined human ocular tissue assays, interventional experiments in C57BL/6-background rd6-type MFRP-knockout and ADIPOR1-knockout mice, and primary bovine RPE cell cultures confirmed that the transmembrane glycoprotein encoded by MFRP is predominantly expressed in RPE cells. MFRP mutation induces shortened axial lengths, whereas physiological MFRP expression supports normal ocular growth regulation.82 Additional genes including PAX6 and ZNF644 modify myopia risk by regulating retinal cell differentiation, proliferation and function.83,84 Environmental stimuli exacerbate myopia progression by perturbing cellular signaling cascades. Prolonged near-work disrupts visual signals received by the retina, inducing dysfunction of cone cells, RGCs and other retinal subtypes to activate inflammatory and senescence cascades.24,37 Insufficient outdoor activity diminishes retinal DA secretion; DA acts as a critical neurotransmitter suppressing axial elongation, and its depletion removes inhibitory constraints on SFs ECM remodeling to accelerate scleral thinning and axial lengthening.85 Additional environmental risk factors including suboptimal lighting and nutritional imbalance elevate myopia susceptibility by disrupting intraocular cellular metabolism and function.86 In studies investigating behavioural risk factors for childhood myopia, screen-use duration serves only as a crude surrogate indicator and is not equivalent to biologically meaningful real-world optical and behavioural exposure parameters. Studies should further distinguish core variables including total screen time, near-working distance, accommodative demand, ambient illuminance, spectral composition, and exposure-time patterns (continuous/intermittent, circadian timing). A large number of current epidemiological studies collect such behavioural data via self-reported questionnaires completed by participants or guardians. This approach is commonly subject to recall bias and misclassification bias, which may lead to underestimation of gene-environment interaction effects or even false-positive associations. Such biases directly compromise the validity of population-level verification for myopia-related hypotheses and hinder the real-world implementation of clinical prediction models. From the perspective of general practice and public health, translating cellular-level pathological pathways such as hypoxia, disrupted light signalling and chronic inflammation into actionable population-prevention indicators relies on standardised objective exposure-collection methods. Wearable devices for recording light exposure and ocular-behaviour provide a technical pathway for objective quantification of the above parameters; nevertheless, further cohort studies are required for validation and standardisation.87 The hypoxic microenvironment serves as a central mediator bridging genetic and environmental factors, exerting profound impacts on the retina-choroid-sclera cellular network. Axial elongation induced by chronic near-work and reduced choroidal perfusion stemming from inadequate outdoor activity both drive hypoxic conditions within retinal and scleral tissues.88,89 Hypoxia activates hypoxia-inducible factors HIF-1α and HIF-2α in SFs, exerting dual effects: first, upregulating MMP-2 expression to accelerate degradation of ECM components including Col I; second, epigenetically suppressing collagen synthesis via histone lactation while promoting fibroblast-to-myofibroblast transdifferentiation. The resulting loss of scleral biomechanical strength eliminates mechanical constraint on intraocular pressure, triggering further axial lengthening. Hypoxia synergizes with inflammatory cascades to amplify pathological scleral remodeling, establishing a self-perpetuating vicious cycle: hypoxia → scleral thinning → axial elongation → aggravated hypoxia, ultimately driving progressive myopia and advancement to high pathological myopia.89 Genetic and environmental factors do not operate independently but exert functional interactions converging upon cells as a shared platform. Genetic susceptibility genes set the cellular threshold and magnitude of response to environmental stimuli, while environmental cues function as trigger signals that activate or amplify genetic pathogenic effects. HIF-1α exemplifies this dynamic interplay: genetic polymorphisms alter HIF-1α protein stability, while hypoxic environmental conditions determine its transcriptional activity. Future research must establish a three-dimensional “gene-environment-cell” interactive model, utilizing induced pluripotent stem cell (iPSC)-derived ocular cells to simulate divergent cellular responses to identical environmental stimuli across distinct genetic backgrounds in vitro. This framework will facilitate identification of high-risk genotype-environment exposure combinations to enable individualized myopia risk stratification and early warning. Furthermore, hypoxia as a core interactive mediator indicates that interventions improving choroidal perfusion and elevating scleral oxygen supply may effectively interrupt this pathogenic vicious cycle via physical modulation. Recent Cellular Biological Breakthroughs in Myopia Research New Discoveries in Pathogenesis New Mechanisms of Cell–Cell Interaction The “senescence-immune axis” hypothesis delivers an innovative framework for myopia mechanistic research. Retinal tissue from myopia animal models harbors abundant senescent cells with elevated expression of core senescence-related genes TP53, CDKN1A and MYC. These senescent cells mediate infiltration of immune populations including γδ T cells, natural killer T (NKT) cells and neutrophils into retinal tissue, forming a senescence-immune regulatory axis that drives myopia progression.68 Activated immune cells secrete pro-inflammatory cytokines to further amplify cellular senescence and scleral remodeling, establishing a positive feedback loop that synergistically accelerates myopia advancement.90 Mechanical tension constitutes the third pivotal component of this regulatory axis: increased mechanical traction from axial elongation directly induces cellular senescence and immune cell infiltration, collectively forming a triangular “mechanical stress-senescence-immune” regulatory cascade. Interventional assays in pigmented guinea pig LIM models demonstrated extensive RGC apoptosis in high myopia, triggering anterograde trans-synaptic degeneration that remodels synapses within the visual cortex to exacerbate visual dysfunction. Feedback regulatory signals originating from remodeled visual cortex may further promote axial elongation.91 Discovery of this mechanism illuminates coordinated pathogenic crosstalk between the retina and visual cortex during myopia development, expanding the current understanding of myopia pathogenesis. The senescence-immune axis hypothesis successfully integrates two formerly discrete research domains within a unified myopia pathogenic framework. It explains the clinical observation that myopia may continue to progress even after removal of the original inciting stimulus, driven by self-sustaining senescence-inflammatory cascades. Subsequent validation via senolytic cell depletion and conditional gene knockout technologies is required to quantify the independent pathogenic contribution of senescent cells to axial elongation. Identification of Novel Biomarkers Development of myopia biomarkers is transitioning from detection of isolated single molecules to integration of multi-dimensional phenotypic readouts, with three biomarker categories exhibiting prominent research progress. Aqueous humor concentrations of TGF-β2, growth differentiation factor 15 (GDF-15) and IL-6 are significantly elevated in high myopia patients and correlate positively with axial length.92,93 GDF-15 levels specifically quantify the severity of retinal injury, conferring high specificity and sensitivity for high myopia diagnosis.90,93 Based on corneal transcriptomic data, single-gene expression levels of TP53, CDKN1A and MYC differ significantly between myopic and normal samples, with individual gene AUC values ranging from 0.8 to 0.9, indicating latent diagnostic value.68 Biomechanical parameters such as corneal cell stiffness and traction force differ markedly between myopic and healthy populations and correlate positively with myopia progression, presenting outstanding translational prospects.94,95 At present, aqueous‑humor‑ and tissue‑derived biomarkers are limited by invasiveness and are difficult to apply for large‑scale screening. Future research should focus on developing detection technologies for exosomal miRNAs or cell‑free DNA based on tears, aqueous humor or blood, as well as “imaging biomarkers” such as artificial‑intelligence‑assisted corneal biomechanical analysis and choroidal texture analysis. As a neurovascular window for non‑invasive systemic observation, ocular molecular and imaging biomarkers can not only predict myopia progression but also hold potential research value for evaluating systemic health status. Further interdisciplinary cohort validation is warranted to achieve genuine early‑warning and dynamic management96 (Table 2). Table 2Potential Myopia BiomarkersBiomarker CategorySpecific BiomarkerSample SourceDetection Performance (AUC/Clinical Utility)Invasiveness GradeClinical ApplicationInflammatory protein biomarkersTGF-β2, IL-6, GDF-1590,91Aqueous humorElevated in high myopia; positively correlated with axial length; GDF-15 reflects retinal injury; no large-sample unified AUCGrade 3: InvasiveHigh myopia risk stratification, complication early warningCellular senescence molecular biomarkersTP53, CDKN1A, MYC mRNA68,69Corneal tissueSingle-gene AUC 0.80–0.90; retrospective analysis only, no prospective cohortGrade 3: Invasive (corneal tissue, scraping/surgery required)Senescence mechanism basic researchNon-coding RNA biomarkersmiR-29a, hsa-miR-142-3p62,63Aqueous humor, peripheral blood exosomesmiR-142-3p positively correlates with axial length; lacks multi-center ROC validationGrade 2: Minimally invasive (blood) / Grade 3: Invasive (aqueous humor)Monitoring scleral remodeling activityCorneal imaging structural biomarkersECD, HEX6,7Slit lamp / confocal microscopy (in vivo)Non-invasive quantification of traction load; differentiates mild, moderate and high myopiaGrade 1: Non-invasivePediatric physical examination, long-term follow-upCorneal cell biomechanical biomarkersCell stiffness, traction force97,98Atomic force microscopy + traction force microscopy (ex vivo)Precise quantification of biomechanical abnormalities; no in vivo detection availableGrade 3: Invasive (ex vivo sampling required)Myopia progression monitoringRetinal imaging biomarkersEZ thickness,39 GC-IPL thickness,27 choroidal thickness15Multimodal fundus OCTEZ thinning indicates photoreceptor damage; choroidal thinning predicts accelerated axial growthGrade 1: Non-invasiveMyopia grading, progression risk predictionSecreted protein biomarkersPRSS5632Retina, eyeballValidated in animal mechanistic studies only; no human AUC or threshold; no body fluid diagnostic evidence for PRSS56Grade 3: InvasiveBasic exploration, awaiting clinical validation Table 2Potential Myopia BiomarkersBiomarker CategorySpecific BiomarkerSample SourceDetection Performance (AUC/Clinical Utility)Invasiveness GradeClinical ApplicationInflammatory protein biomarkersTGF-β2, IL-6, GDF-1590,91Aqueous humorElevated in high myopia; positively correlated with axial length; GDF-15 reflects retinal injury; no large-sample unified AUCGrade 3: InvasiveHigh myopia risk stratification, complication early warningCellular senescence molecular biomarkersTP53, CDKN1A, MYC mRNA68,69Corneal tissueSingle-gene AUC 0.80–0.90; retrospective analysis only, no prospective cohortGrade 3: Invasive (corneal tissue, scraping/surgery required)Senescence mechanism basic researchNon-coding RNA biomarkersmiR-29a, hsa-miR-142-3p62,63Aqueous humor, peripheral blood exosomesmiR-142-3p positively correlates with axial length; lacks multi-center ROC validationGrade 2: Minimally invasive (blood) / Grade 3: Invasive (aqueous humor)Monitoring scleral remodeling activityCorneal imaging structural biomarkersECD, HEX6,7Slit lamp / confocal microscopy (in vivo)Non-invasive quantification of traction load; differentiates mild, moderate and high myopiaGrade 1: Non-invasivePediatric physical examination, long-term follow-upCorneal cell biomechanical biomarkersCell stiffness, traction force97,98Atomic force microscopy + traction force microscopy (ex vivo)Precise quantification of biomechanical abnormalities; no in vivo detection availableGrade 3: Invasive (ex vivo sampling required)Myopia progression monitoringRetinal imaging biomarkersEZ thickness,39 GC-IPL thickness,27 choroidal thickness15Multimodal fundus OCTEZ thinning indicates photoreceptor damage; choroidal thinning predicts accelerated axial growthGrade 1: Non-invasiveMyopia grading, progression risk predictionSecreted protein biomarkersPRSS5632Retina, eyeballValidated in animal mechanistic studies only; no human AUC or threshold; no body fluid diagnostic evidence for PRSS56Grade 3: InvasiveBasic exploration, awaiting clinical validation Potential Myopia Biomarkers New Breakthroughs in Cell-Targeted Intervention Strategies Novel Drug Delivery Systems Exosome-mediated ocular targeted drug delivery represents a transformative technological breakthrough. Combined FDM interventional assays in pigmented guinea pigs and in vitro HSFs experiments confirmed that quercetin-loaded exosomes (Exo-Que) precisely accumulate in the retina and SFs to enhance drug bioavailability. By inhibiting ER stress and ferroptosis, they alleviate axial elongation and retinal inflammation, achieving therapeutic efficacy comparable to 0.1% atropine without mydriasis and other adverse reactions.80 To address poor aqueous stability of atropine solutions, atropine-loaded ocular dissolvable films have been developed. These thin, flexible transparent films with low water content rapidly disintegrate in tear fluid, markedly improving drug stability and offering a safer, more efficient ocular delivery formulation for myopia treatment.99 The greatest advantages of exosome delivery systems lie in solving two core challenges: targeted tissue penetration and specific cell delivery. As natural nanocarriers, exosomes can cross the blood-retinal barrier and achieve cell-specific targeting via surface modification. However, large-scale production, purification quality control and long-term safety remain major obstacles to clinical translation. From a clinical translation perspective, reformulated ocular dosage forms such as eye films, sustained-release rings and nanomicelles possess lower industrialization barriers and may enter clinical practice earlier. Cutting-edge technologies including exosomes and gene editing require perfected production standards and long-term safety evaluation systems before widespread clinical application. Anti-Inflammatory Targeted Therapy Multiple advances have been achieved in research targeting inflammatory pathways. Diacerein, an IL-1β inhibitor, blocks the MEK/ERK and NF-κB cascades in the retina and sclera of FDM animal models, inhibiting scleral ECM remodeling and mitigating axial elongation.100 Resveratrol suppresses the NF-κB and MAPK pathways while enhancing scleral collagen synthesis capacity, improving scleral thickness and biomechanical stiffness.101,102 Cross-sectional population studies of Taiwanese children covered by national medical insurance, alongside FDM animal and in vitro cell experiments, confirmed that cyclosporin A downregulates pro-inflammatory factors via suppressing T cell activation and exerts mild inhibitory effects on myopia progression.103 Notably, existing research indicates that monotherapy with anti-inflammatory agents yields weaker myopia control efficacy than atropine, demonstrating that inflammation functions as an amplifying rather than initiating factor in myopia progression. Anti-inflammatory treatments are therefore more suitable as adjuvant components combined with anti-hypoxia and anti-senescence strategies. Meanwhile, most current studies adopt prophylactic drug administration designs, which differ from clinical therapeutic scenarios; efficacy under curative dosing regimens remains to be further verified. Application of Gene Editing Technology CRISPR/Cas9 gene editing has achieved breakthroughs in preclinical myopia research. Knockout of TP53 and CDKN1A suppresses cellular senescence pathways, reduces retinal cell apoptosis, inhibits scleral ECM remodeling and alleviates axial lengthening in myopia models.68 Knockout of Fos inhibits RGC apoptosis, relieves trans-synaptic degeneration and preserves integrity of the visual pathway.91 While gene editing holds potential for curative myopia treatment, safety constitutes the core barrier to clinical translation. Permanent knockout of core tumor suppressor genes such as TP53 carries elevated oncogenic risk, alongside unavoidable off-target effects and immune reactions, rendering permanent gene knockout strategies highly risky and low-feasibility for chronic non-lethal diseases like myopia. More viable future directions include reversible epigenetic regulation, transient mRNA/protein delivery, and temporary gene editing restricted to developmental windows. In addition, although research on Fos knockout alleviating trans-synaptic degeneration is innovative, it remains unconfirmed whether visual cortical synaptic remodeling constitutes a cause or consequence of myopia, requiring additional causal validation experiments. New Insights into Cellular Mechanisms of Physical Intervention The cellular mechanisms of repeated low-level red light (RLRL) therapy have been further elucidated: RLRL modulates retinal inflammatory pathways to reduce pro-inflammatory factor expression, improves choroidal perfusion to alleviate the hypoxic microenvironment, and suppresses retinal cellular senescence and apoptosis, thereby inhibiting axial elongation.104–106 Multiple clinical trials have verified its non-invasive, safe inhibitory effect on myopia progression in adolescents.107 The preventive mechanisms of outdoor light exposure have also been validated: natural light promotes retinal DA secretion to inhibit scleral ECM degradation and maintain scleral homeostasis, while regulating retinal circadian rhythms to optimize visual signal processing, jointly exerting anti-myopia effects.97,98,108 Physical interventions offer the advantages of multi-target action, low risk and easy popularization, yet clear dose-effect boundaries must be defined. Red light therapy follows an inverted U-shaped dose response curve, with excessive irradiation posing risks of macular injury. The effective dosage of outdoor light requires quantitative standardization to formulate implementable public health guidelines. Future research should develop wearable light recorders paired with mobile applications to generate individualized light exposure prescriptions. Innovation of Research Techniques and Methods Single-cell RNA sequencing resolves heterogeneity among retinal glial cells and SFs, explaining inconsistent results from bulk sequencing experiments and providing powerful tools for precise identification of key cells and molecular targets.35 Combined atomic force microscopy and traction force microscopy enable precise quantitative detection of corneal biophysical properties, comprehensively evaluating cellular stiffness, adhesion and traction force.109,110 Functional magnetic resonance imaging detects cerebral blood flow and metabolic activity in the visual cortex, while electrophysiology records neuronal electrical signals. Combined application of both modalities enables evaluation of trans-synaptic degeneration induced by RGC apoptosis, establishing a novel method to assess visual pathway integrity.91,111 Longitudinal multi-center cohort studies of children and adolescents validated an artificial intelligence myopia progression prediction model (MPPM) built on the Transformer architecture integrated with causal reasoning modules. The model accurately predicts 10-year trajectories of spherical equivalent refraction and axial length in children and adolescents, and quantitatively quantifies individualized protective benefits of four mainstream interventions: 0.01% atropine, orthokeratology lenses, peripheral defocus spectacles and RLRL. Internal validation yielded a coefficient of determination R2 of 0.94 for spherical equivalent prediction, delivering an efficient digital tool for stratified precision management of juvenile myopia.112 It should be noted that most current artificial-intelligence-based myopia progression prediction models only incorporate demographic, refractive and ocular biometric parameters, and have not integrated objectively validated behavioural-optical exposure variables, which constitutes a major limitation for the real-world implementation of such models. Technological innovation is reshaping myopia research paradigms, with multi-modal data fusion set to become mainstream in future work. Integration of single-cell omics, structural imaging, biomechanical metrics and long-term clinical follow-up data within a unified AI model enables prediction not only of whether myopia will progress, but also individual responsiveness to distinct interventions, truly realizing precision medicine. Attention must be paid to the “black-box” limitation and training dataset bias of AI models, requiring improved interpretability and external cohort validation (Table 3). Table 3Myopia Intervention StrategiesIntervention CategorySpecific InterventionCore Target/MechanismValidation ModelEvidence TierPharmacological interventionLow-concentration atropine110M receptor blockade; anti-inflammation, downregulates MMP2, enhances scleral collagen synthesisMulti-center Phase III ATOM/LAMP/BLINK cohorts, guinea pig LIMTier I: Established clinical regimenOptical physical interventionPeripheral defocus spectacles / Ortho-K lenses110Corrects peripheral hyperopic defocus; increases retinal DA, improves choroidal perfusionPediatric RCT cohorts, non-human primatesTier I: Established clinical regimenOptical physical interventionRepeated low-level red light (RLRL)110Improves choroidal hypoxia, inhibits HIF-1α, alleviates ER stress and inflammationPediatric clinical trials, guinea pig FDMTier I: Established clinical regimenBehavioral physical intervention≥2 hours daily outdoor natural light110Activates cone photoreceptors, increases DA, stabilizes circadian rhythm, suppresses senescenceEpidemiological cohorts, mouse light exposure modelsTier I: Established clinical regimenSmall-molecule targeted drugsDiacerein, resveratrol95,96,99Inhibits IL-1β, blocks NF-κB/MAPK pathways, antioxidantHamster/mouse FDM, human RPE/SFs in vitroTier III: Basic experimental stageSmall-molecule targeted drugs4-PBA,80 quercetin monomer78Alleviates SF ER stress, inhibits ferroptosis, clears senescent cellsGuinea pig/mouse SFs in vitroTier III: Basic experimental stageNovel ocular formulationsAtropine ocular dissolvable film94Optimizes stability and delivery efficiency; sustained-release M receptor antagonismIn vitro release + ocular pharmacokinetics, pigmented guinea pig FDMTier II: Formulation optimization stageNovel ocular formulationsQuercetin-loaded exosomes (Exo-Que)80Penetrates blood-retinal barrier; simultaneously anti-inflammatory, anti-stress, anti-ferroptoticPigmented guinea pig FDM, primary human cellsTier III: Basic research (formulation under optimization)Gene / epigenetic interventionCRISPR knockout of TP53, CDKN1A;68,69 Fos90Inhibits cellular senescence, reduces RGC degeneration, reverses scleral remodelingC57BL/6 gene-edited miceTier III: Basic research, high translational riskMetabolic nutritional interventionExogenous glycine supplementation67Inhibits SF ferroptosis, enhances COL1A1 synthesis, antioxidantLIM guinea pigsTier III: Animal experiments, lacks human evidenceImmune-targeted interventionMET inhibitors (lactoferrin);66 cyclosporin A101Inhibits macrophage MET release; blocks T cell pro-inflammatory activationMouse FDM model, Taiwanese pediatric cross-sectional studyTier II: Combination intervention; limited cyclosporin A evidence Table 3Myopia Intervention StrategiesIntervention CategorySpecific InterventionCore Target/MechanismValidation ModelEvidence TierPharmacological interventionLow-concentration atropine110M receptor blockade; anti-inflammation, downregulates MMP2, enhances scleral collagen synthesisMulti-center Phase III ATOM/LAMP/BLINK cohorts, guinea pig LIMTier I: Established clinical regimenOptical physical interventionPeripheral defocus spectacles / Ortho-K lenses110Corrects peripheral hyperopic defocus; increases retinal DA, improves choroidal perfusionPediatric RCT cohorts, non-human primatesTier I: Established clinical regimenOptical physical interventionRepeated low-level red light (RLRL)110Improves choroidal hypoxia, inhibits HIF-1α, alleviates ER stress and inflammationPediatric clinical trials, guinea pig FDMTier I: Established clinical regimenBehavioral physical intervention≥2 hours daily outdoor natural light110Activates cone photoreceptors, increases DA, stabilizes circadian rhythm, suppresses senescenceEpidemiological cohorts, mouse light exposure modelsTier I: Established clinical regimenSmall-molecule targeted drugsDiacerein, resveratrol95,96,99Inhibits IL-1β, blocks NF-κB/MAPK pathways, antioxidantHamster/mouse FDM, human RPE/SFs in vitroTier III: Basic experimental stageSmall-molecule targeted drugs4-PBA,80 quercetin monomer78Alleviates SF ER stress, inhibits ferroptosis, clears senescent cellsGuinea pig/mouse SFs in vitroTier III: Basic experimental stageNovel ocular formulationsAtropine ocular dissolvable film94Optimizes stability and delivery efficiency; sustained-release M receptor antagonismIn vitro release + ocular pharmacokinetics, pigmented guinea pig FDMTier II: Formulation optimization stageNovel ocular formulationsQuercetin-loaded exosomes (Exo-Que)80Penetrates blood-retinal barrier; simultaneously anti-inflammatory, anti-stress, anti-ferroptoticPigmented guinea pig FDM, primary human cellsTier III: Basic research (formulation under optimization)Gene / epigenetic interventionCRISPR knockout of TP53, CDKN1A;68,69 Fos90Inhibits cellular senescence, reduces RGC degeneration, reverses scleral remodelingC57BL/6 gene-edited miceTier III: Basic research, high translational riskMetabolic nutritional interventionExogenous glycine supplementation67Inhibits SF ferroptosis, enhances COL1A1 synthesis, antioxidantLIM guinea pigsTier III: Animal experiments, lacks human evidenceImmune-targeted interventionMET inhibitors (lactoferrin);66 cyclosporin A101Inhibits macrophage MET release; blocks T cell pro-inflammatory activationMouse FDM model, Taiwanese pediatric cross-sectional studyTier II: Combination intervention; limited cyclosporin A evidence Myopia Intervention Strategies Discussion and Outlook Existing myopia interventions can be categorized into three tiers of evidence based on the completeness of clinical trial data. Tier 1 encompasses conventional clinical interventions validated via multi-center Phase III trials, including 0.01%~0.04% low-concentration atropine, orthokeratology lenses (Ortho-K), peripheral defocus spectacles, RLRL and outdoor activity. Global cohorts such as ATOM, LAMP, BLINK and ROMIO confirmed axial control efficiency ranging from 30% to 70%; 0.02% atropine outperforms 0.01% with mild, manageable short-term photophobia and near blur adverse effects. Ortho-K and defocus lenses achieve prominent control effects, while outdoor activity incurs zero cost and is suitable for campus promotion. Core barriers to widespread implementation include high equipment purchase and maintenance costs, poor children compliance, and lack of unified global standardized diagnosis and treatment protocols. Furthermore, most existing clinical trials only feature 1–3 year follow-up periods, with abundant data from East Asian populations but insufficient evidence from European and American ethnic groups.113 Tier 2 consists of cell-targeted new drugs under Phase I/II clinical development, such as non-atropine eye drops GPN00884. This agent has completed Phase I safety trials in Chinese adults and initiated Phase IIa trials for children aged 6–12 in October 2025, yet no long-term axial control endpoints over 2 years are available, precluding large-scale clinical application at present. Tier 3 interventions remain confined to mouse and guinea pig animal experiments. While quercetin exosomes, MET inhibitors, nucleic acid therapeutics and CRISPR editing demonstrate efficacy in preclinical animal models, they face unresolved challenges including purification quality control, off-target risks and oncogenic hazards, with no human clinical trial data and a projected clinical translation timeline of at least 5–10 years. In addition, aqueous humor biomarkers such as TGF-β2 and GDF-15, alongside corneal mechanical imaging markers, have only been verified in adult pathological myopia samples, lacking multi-center prospective cohort support from school-age children and thus unsuitable for large-scale juvenile screening and early warning. To resolve fragmentation and disconnection between tissue regulatory axes observed in previous mechanistic reviews, this paper constructs a five-level sequential integrated framework: upstream photoreceptive initiation center (retina) – signal relay hub (RPE) – microenvironment amplifier (choroid + immune cells) – terminal effector cells (SFs) – secondary mechanical feedback unit (corneal cells). The framework incorporates all key ocular cell populations: rod/cone photoreceptors, ipRGCs, Müller/astrocyte/microglia, RPE, choroidal endothelial cells, infiltrating macrophages, Wnt5ahi SFs subpopulations, and corneal epithelial/stromal/endothelial cells. The complete pathological cascade proceeds as follows: external stimuli including prolonged near-work, insufficient light exposure and abnormal spectral composition first disrupt cone phototransduction, acting as the initiating trigger of myopia. Retinal neurons and glia then secrete DA, VIP and pro-inflammatory cytokines which are transmitted to RPE. RPE integrates three types of input signals (phototransduction, inflammation, hypoxia) to function as a central relay node. Subsequently, RPE modulates choroidal blood perfusion to generate a hypoxic microenvironment, recruiting and activating macrophages and microglia that secrete abundant SASP factors, MMPs and pro-inflammatory mediators to establish a senescence-immune positive feedback loop amplifying pathological signals. These regulatory molecules diffuse through the extracellular fluid to the posterior sclera, inhibiting collagen synthesis and activating matrix degradation pathways to induce scleral remodeling and excessive axial elongation. Axial stretching generates mechanical traction that disrupts corneal cytoskeletons and activates the complement system, reducing corneal biomechanical stability. Corneal parameters only serve as non-invasive readouts reflecting intraocular remodeling burden and do not drive axial growth. Core pathways including NF-κB inflammatory signaling, TP53-mediated senescence cascades, IRE1/PERK ER stress axes, HIF-1α hypoxia signaling and dual-functional TGF-β permeate all tiers of the framework, forming a multi-layered cross-talk network across tissues that systematically reconstructs the complete multicellular synergistic pathogenic closed loop of myopia. Although this review systematically elaborates the cellular biological basis of myopia and delineates the multi-cell, multi-pathway network spanning retinal photoreceptor dysfunction to scleral fibroblast remodeling, fundamental bottlenecks persist in integrating existing findings into a complete pathogenic circuit and bridging translational gaps between basic research and clinical practice. First, most current mechanistic research relies on FDM and LIM animal models, which possess substantial limitations in clinical translatability. Inherent species differences exist in ocular developmental cycles, scleral collagen composition, and regulatory mechanisms of inflammation and senescence. Animal models induce short-term severe pathological myopia, which differs drastically from the chronic, mild, cumulative progression of physiological and moderate myopia in children and adolescents. Standardized experimental conditions in animals cannot replicate complex human confounding factors such as age, genetic background, eye-use habits and outdoor activity. Drug dosages and intervention durations applied in animal studies mismatch clinical regimens, meaning efficacy and safety conclusions cannot be directly extrapolated to humans. This constitutes a major barrier delaying the clinical translation of basic mechanistic discoveries into precise myopia control. Second, the causal relationship between cellular senescence and chronic inflammation remains unresolved, creating a dilemma for therapeutic target selection. This review confirms synergistic effects of the senescence-immune axis, wherein senescent cells recruit immune cells via SASP and immune-derived inflammatory factors further exacerbate senescence and scleral remodeling. However, all existing relevant studies only report cross-sectional correlations or post-intervention observations, lacking time-series experiments to distinguish their sequential activation order. The primary initiator of this positive feedback loop directly dictates therapeutic strategy selection: if cellular senescence occurs upstream, senolytic agents represent first-line candidates; if chronic inflammation serves as the initiating factor, anti-inflammatory antibody therapy is preferable. Future research must adopt inducible cell lineage tracing and conditional gene knockout technology to temporally delineate their regulatory sequence and provide evidence for clinical trial target screening. Third, existing mechanistic models oversimplify signaling networks by ignoring environment-dependent functional switching of signaling molecules. TGF-β serves as a typical example: it promotes ECM synthesis and scleral homeostasis via the SMAD2/3 pathway yet accelerates ECM degradation by activating the TAK1-IKK-NF-κB axis. Its divergent biological outcomes depend on local mechanical stress, inflammatory milieu and cell type. Most current experiments are conducted under static, single experimental conditions, failing to recapitulate dynamic in vivo microenvironments, resulting in static, decontextualized pathway models. Future research must construct coupled biomechanical-biochemical in vitro models combined with spatial transcriptomics to compare TGF-β transcriptional profiles across scleral regions under varying mechanical load and identify molecular switches governing its functional transformation. In addition, preclinical evaluation of novel interventions suffers from bias prioritizing efficacy over safety. While exosome-delivered quercetin and CRISPR-mediated TP53 knockout effectively reverse axial lengthening in animal models, long-term human safety data remain insufficient. TP53 knockout elevates oncogenic risk in retinal tissue, yet existing research fails to report tumor incidence and genomic stability metrics. Meanwhile, RLRL therapy carries an inverted U-shaped dose risk of macular photoreceptor damage with no multi-year long-term follow-up data to confirm safety. Therefore, preclinical research for all novel interventions must equally prioritize safety indicators including off-target rate and genomic instability alongside efficacy endpoints, establishing comprehensive safety evaluation systems. Current cellular biological research confirms myopia as a systemic disease involving coordinated dysfunction of multiple tissues, cells and signaling pathways. Future research need not solely pursue identification of additional novel targets, but should center on three core unresolved bottlenecks: temporal causal relationships, environment-dependent signaling functionality, and clinical translational safety boundaries. Only by overcoming these barriers can myopia management advance from symptomatic mitigation toward etiology-based precision targeted therapy, contributing to global visual health. Meanwhile, from the perspective of general practice, myopia is not merely a refractive-specialty disease. The underlying universal cellular pathological pathways including senescence-inflammation-hypoxia share biological intersections with multiple systemic chronic diseases. As a non-invasively observable neurovascular window, further validation of ocular omics and ocular biomarkers holds promise for broader population-level preliminary health risk screening in the future.